Latest Hotspot

AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline

12 June 2024
3 min read

AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial. ABBV-383 is a unique bispecific antibody T-cell engager targeting B-cell maturation antigen (BCMA) and CD3, featuring bivalent BCMA-binding domains that offer high avidity for BCMA and a low-affinity CD3 binding domain. Currently, ABBV-383 is being tested in a multicenter, randomized, open-label Phase 3 study, where it is being compared to standard therapies in patients with relapsed or refractory multiple myeloma (r/r MM) who have undergone at least two prior treatments.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"Even with significant progress in treatment, the majority of patients with multiple myeloma will eventually face relapse. For those with advanced stages of the disease, particularly in community settings, access to new treatment options is often restricted, and existing treatments come with substantial burdens, such as frequent dosing," stated Dr. Peter Voorhees, clinical professor of medicine and director of plasma cell disorders at Atrium Health Levine Cancer Institute. "The CERVINO Phase 3 trial aims to assess the efficacy of ABBV-383 with a monthly dosing schedule, and we are eager to analyze the forthcoming data."

Multiple myeloma, a blood cancer marked by the abnormal growth of plasma cells, can lead to damage in various organs and ranks as the second most common blood cancer globally. Approximately 176,000 people worldwide were diagnosed with multiple myeloma in 2020, with 117,000 deaths resulting from the disease.

"The initiation of the CERVINO Phase 3 trial signifies a significant advancement in AbbVie's ongoing effort to enhance oncology treatments and improve the standard of care for blood cancer patients," remarked Mariana Cota Stirner, M.D., vice president and therapeutic area head of oncology and hematology at AbbVie. "From the start of treatment, ABBV-383 will be evaluated with monthly dosing to potentially simplify the treatment process for both doctors and patients, pending positive trial outcomes."

ABBV-383 is an investigational, unique BCMA x CD3 bispecific antibody T-cell engager, featuring bivalent high-avidity BCMA-binding domains, a low-affinity CD3-binding domain designed to mitigate cytokine release, and a silenced Fc tail engineered for an extended half-life, possibly supporting dosing intervals of every four weeks. The clinical importance of these structure-activity relationships is yet to be determined.

BCMA is predominantly expressed on malignant plasma cells in multiple myeloma, making it an ideal therapeutic target. BCMA is crucial for the survival of myeloma cells, as it fosters their growth and prevents their apoptosis.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of June 11, 2024, there are 35 investigational drugs for the BCMA and CD3 targets, including 15 indications, 50 R&D institutions involved, with related clinical trials reaching 117, and as many as 9265 patents.

Etentamig is intended for the treatment of multiple myeloma, immunoglobulin light-chain amyloidosis, plasma cell myeloma refractory, and relapse multiple myeloma. The drug has reached Phase 3 of development globally and has received IND approval in China. 

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 12
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 12
12 June 2024
Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Amgen Announces Positive Phase 3 Trial Results for Uplizna® in Treating IgG4-Related Disease
Latest Hotspot
3 min read
Amgen Announces Positive Phase 3 Trial Results for Uplizna® in Treating IgG4-Related Disease
12 June 2024
Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).
Read →
Boston Pharma Presents Data at EASL 2024: BOS-580 Improves Lipid Profiles in MASH Patients
Latest Hotspot
3 min read
Boston Pharma Presents Data at EASL 2024: BOS-580 Improves Lipid Profiles in MASH Patients
12 June 2024
Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.
Read →
Nutcracker Therapeutics Highlights Enhanced Efficacy of NTX-472 for B Cell Lymphoma at 2024 ASCO
Latest Hotspot
3 min read
Nutcracker Therapeutics Highlights Enhanced Efficacy of NTX-472 for B Cell Lymphoma at 2024 ASCO
12 June 2024
Nutcracker Therapeutics Showcases Improved Efficacy of B Cell Lymphoma Drug Candidate NTX-472 at 2024 ASCO Meeting.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.